Navigating A Key Inflection Point In Biosimilar Sector M&A
A significant uptick has occurred in mergers and acquisitions in the biosimilars sector, with deal value approximating $13 billion in the first nine months of 2026 alone, and mimicking the 15%...To view the full article, register now.
Already a subscriber? Click here to view full article